Short Interest in Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Decreases By 13.9%

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a large drop in short interest during the month of March. As of March 31st, there was short interest totaling 430,841 shares, a drop of 13.9% from the March 15th total of 500,465 shares. Based on an average trading volume of 851,376 shares, the days-to-cover ratio is currently 0.5 days. Approximately 17.0% of the shares of the company are short sold.

Hedge Funds Weigh In On Aspire Biopharma

A number of large investors have recently modified their holdings of ASBP. XTX Topco Ltd grew its position in shares of Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock valued at $35,000 after purchasing an additional 237,620 shares in the last quarter. Jane Street Group LLC grew its position in shares of Aspire Biopharma by 2,252.1% during the 4th quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock valued at $91,000 after purchasing an additional 658,886 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Aspire Biopharma during the 3rd quarter valued at $28,000. 19.17% of the stock is currently owned by institutional investors.

Aspire Biopharma Price Performance

Shares of ASBP stock opened at $0.30 on Friday. The company’s fifty day simple moving average is $1.16 and its two-hundred day simple moving average is $4.80. The stock has a market capitalization of $807,000.00, a price-to-earnings ratio of -0.02 and a beta of 0.99. Aspire Biopharma has a 1 year low of $0.28 and a 1 year high of $35.01.

Aspire Biopharma (NASDAQ:ASBP) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company had revenue of $0.00 million during the quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Aspire Biopharma to a “sell” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.